Skip to main
SEPN

Septerna Inc (SEPN) Stock Forecast & Price Target

Septerna Inc (SEPN) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Septerna is on track with its pipeline and a strong outlook for its clinical candidates in the endocrinology, immunology and inflammation, and metabolic disease areas. Its proprietary Native Complex Platform has shown promising activity in preclinical studies and is now being evaluated in a Phase 1 trial to evaluate the safety and tolerability of SEP-479 in healthy adult volunteers. Septerna's strong partnership with Novo Nordisk A/S provides additional financial support for its research and development efforts and its multiple discovery-stage programs have the potential to further expand its pipeline. Overall, Septerna's advancements and positive clinical data for its various candidates make it an attractive investment opportunity.

Bears say

Septerna is a clinical-stage biotechnology company that has yet to generate any significant revenue from its products or services. Despite its promising pipeline of product candidates, the company is still in the early stages of commercialization and faces significant competition in the endocrinology, immunology and inflammation, and metabolic disease markets. Additionally, its negative cash flow and high operating expenses suggest that the company may struggle to sustain itself in the long term without significant funding or successful product launches.

Septerna Inc (SEPN) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Septerna Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Septerna Inc (SEPN) Forecast

Analysts have given Septerna Inc (SEPN) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Septerna Inc (SEPN) has a Strong Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Septerna Inc (SEPN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.